The Scent of a Woman

0 Shares
0
0
0

In many species, female body odors reflect their reproductive status, and odors around the time of ovulation attract males, resulting in behavioral and/or physiological changes. In humans, several studies have suggested that female body odor signals periods of high fertility. For instance, vaginal secretions collected during the preovulatory and ovulatory phases are rated as more pleasant than those from the menstrual, early luteal, or late luteal phases. Additionally, axillary, armpit odors during the fertile phase are perceived by men as more pleasant, sexy, or attractive compared to those during the menstrual and luteal phases. Another study indicated that high-fertility scents collected from the armpit were chosen as more attractive than low-fertility scents. The fact that hormonal contraception results in the loss of these effects suggests that attractiveness is dependent on female hormones. It has been suggested that women’s behavior and physical attractiveness may serve as identifiable cues to fertility, and that men’s preferences are likely to increase for physical cues associated with high estrogen levels.

Changes in axillary volatile compounds within the menstrual cycle may be attributed to fluctuations in hormone concentrations, including estradiol and progesterone, within the cycle. In particular, estradiol receptors are expressed in many tissues and are believed to be involved in systemic metabolism and sweat gland secretory activity. Studies have revealed that amino acids and their derivatives in blood tend to increase during the menstrual phase and decrease during the luteal phase, whereas phospholipids and other substances in blood increase during the follicular phase, the first half of the menstrual cycle, and decrease during the luteal phase the second 14 days of the menstrual cycle. In a recent study the authors demonstrated that long-chain fatty acids, including tetradecanoic acid and (Z)-9-hexadecenoic acid, increase from the follicular phase to around ovulation and decrease during the luteal phase. This possibly reflects the degradation of blood-derived lipids on the skin surface, which increase during the follicular phase. Moreover, several compounds also increased during the follicular phase, and some of these tended to further increase during ovulation, suggesting the strong effects of estradiol on the variability of amounts of each compound during the menstrual cycle.

Researchers have identified three Ovulation-phase-increasing compounds namely: (1) (E)-geranylacetone: it is produced by oxidation of squalene and emits a floral or green odor quality and is among the prominently recognized substances in humans. (2) Tetradecanoic acid: it has an oxidized sebum odor quality and is detected in skin, saliva, breast milk, and amniotic fluid. Its primary production pathway is believed to be triglyceride hydrolysis by skin bacteria lipase or it may be derived from blood owing to its ubiquitous presence in cells and plasma. Human amniotic fluid and breast milk contain this odorant to which newborns exhibit a suckling response. (3) (Z)-9-hexadecenoic acid: commonly termed palmitoleic acid, it is nearly odorless. It is derived from palmitic acid and is presumed to be a precursor to (E)-2-nonenal, a compound representative of the odor of aging “aging odor,” which is generated through its breakdown by skin bacteria

Odor from the three Ovulation-phase-increasing compounds induces a sense of comfort and relaxation in men. Furthermore, when the odor of the basal axillary odor was combined with the three Ovulation-phase increasing compounds, it not only enhanced the attractiveness of low-attractive-level female faces but also suppressed the increase in salivary amylase, an indicator of stress-related bad odor, in comparison to the odor of the basal axillary scent alone. It has been reported that pleasant essential oil (like rose), enhance facial attractiveness, but it is noteworthy that such effects may also be present in components of body odor that fluctuate with the menstrual cycle.

In addition to body odor, several reports indicate various physical changes in women during the menstrual cycle. The voice during the ovulation period is perceived as the most attractive to men, and it has been demonstrated that the frequency of the voice also increases during the fertile phase. Photographs of a female face during the ovulation phase are perceived as more desirable than other times The redness of the face has been reported to decrease after the first day of menstruation and increases toward ovulation, although it is not detectable by the naked eye. It appears that physical features that enhance appeal to the opposite sex are heightened during the ovulation phase.

Sources

https://www.cell.com/iscience/fulltext/S2589-0042(25)01348-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004225013483%3Fshowall%3Dtrue

 

0 Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like
Autoimmune Diseases in Women

Autoimmune DisordersWhy Do Autoimmune Diseases Disproportionately Affect Women?

Autoimmune diseases are the third most prevalent disease category, outpaced only by cancer and heart disease. Autoimmune diseases occur when the immune system, which typically defends the body against harmful invaders like bacteria and viruses, begins to attack healthy tissues causing inflammation and damage. These disorders disproportionately affect women, with approximately 80% of all autoimmune disease patients being women. Understanding why these diseases occur more frequently in women, their implications, and how they can be managed is a crucial area of study in modern medical science.

Neurogenerative DisordersAre Estrogens Neuroprotective – Do they Slow or Prevent Alzheimers?

Estrogens are pivotal regulators of brain function, exerting profound effects from early embryonic development to aging. Extensive experimental evidence underscores the multifaceted protective roles of estrogens on neurons and neurotransmitter systems, particularly in the context of Alzheimer’s Disease (AD). Studies have consistently revealed a greater risk of Alzheimer’s Disease (AD) development in women compared to men, with postmenopausal women exhibiting heightened susceptibility. This connection between hormone levels and long-term estrogen deprivation highlights the significance of estrogen signaling in Alzheimer’s Disease (AD) progression.

FertilityStudy Finds Simple Maternal Biomarker Test Reduces Neonatal Complications

Preterm birth is defined as any birth that occurs before 37 weeks of gestation and is the leading cause of illness and death among newborns. The 2023 March of Dimes Report Card reveals that more than one in ten infants were born prematurely in the United States in the past five consecutive years and for the third consecutive year, the March of Dimes Annual Report Card has given the United States a D+ for the country’s persistently high preterm birth rate.
Femtech

Free ArticlesFemtech, the Future of Women’s Healthcare

FemTech, short for female technology, refers to software and services that utilize technology to address women's health needs. The emergence of women’s health technologies, or ‘FemTech’, is a significant advancement in women’s healthcare and reproductive rights. These rights, which include the right to abortion, contraception, and equitable fertility treatment, are essential to guaranteeing women’s bodily autonomy and human dignity. The FemTech industry promises to empower women by offering them tools to better understand and manage their reproductive health through a solid empowerment narrative. While offering potential for improved access to healthcare and personalized solutions, FemTech also faces challenges related to data privacy, regulatory issues, and the need for more robust scientific evidence. 
Cardiovascular Disease in Women

Cardiovascular DiseaseCardiovascular Disease in Women Under-Diagnosed and Undertreated

Cardiovascular disease (CVD) affects 6.6 million women in the United States annually and is the leading source of morbidity and mortality among women. Among women diagnosed with cardiovascular disease, 2.7 million have a history of MI - Myocardial Infarction (heart attack). Each year more than 53,000 women die of a heart attacks and 262,000 are hospitalized because of CVD. One in 4 female patients presenting with a first myocardial infarction will die.